GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Price-to-Owner-Earnings

Luye Pharma Group (HKSE:02186) Price-to-Owner-Earnings : 59.80 (As of May. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Price-to-Owner-Earnings?

As of today (2024-05-18), Luye Pharma Group's share price is HK$2.99. Luye Pharma Group's Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$0.05. It's Price-to-Owner-Earnings for today is 59.80.


The historical rank and industry rank for Luye Pharma Group's Price-to-Owner-Earnings or its related term are showing as below:

HKSE:02186' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.32   Med: 29.3   Max: 399.09
Current: 58.63

During the past 13 years, the highest Price-to-Owner-Earnings of Luye Pharma Group was 399.09. The lowest was 7.32. And the median was 29.30.


HKSE:02186's Price-to-Owner-Earnings is ranked worse than
78.62% of 421 companies
in the Drug Manufacturers industry
Industry Median: 28.28 vs HKSE:02186: 58.63

As of today (2024-05-18), Luye Pharma Group's share price is HK$2.99. Luye Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.16. Therefore, Luye Pharma Group's PE Ratio for today is 19.17.

As of today (2024-05-18), Luye Pharma Group's share price is HK$2.99. Luye Pharma Group's EPS without NRI for the trailing twelve months (TTM) ended in was HK$0.12. Therefore, Luye Pharma Group's PE Ratio without NRI for today is 25.13.

During the past 13 years, Luye Pharma Group's highest PE Ratio without NRI was 42.07. The lowest was 7.56. And the median was 17.89.


Luye Pharma Group Price-to-Owner-Earnings Historical Data

The historical data trend for Luye Pharma Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Price-to-Owner-Earnings Chart

Luye Pharma Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.95 - - 332.73 73.14

Luye Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 332.73 - 73.14

Competitive Comparison of Luye Pharma Group's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Price-to-Owner-Earnings falls into.



Luye Pharma Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Luye Pharma Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.99/0.05
=59.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Luye Pharma Group  (HKSE:02186) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Luye Pharma Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group (HKSE:02186) Business Description

Traded in Other Exchanges
Address
No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Luye Pharma Group (HKSE:02186) Headlines

No Headlines